Rhythm Biosciences Advances in Cancer Diagnostics with Strategic Expansion

Rhythm Biosciences Ltd (ASX: RHY) continues to solidify its position as a leader in predictive cancer diagnostics, marked by significant milestones in Q3 FY25. Central to its achievements is the progression of ColoSTAT®, a blood-based test for colorectal cancer, now in final verification with clinical validation preparation underway. The integration of Genetype™, a genetic risk assessment platform, was completed ahead of schedule, bolstering RHY’s diagnostic capabilities. This quarter also saw the successful relaunch and initial sales of Genetype™ under RHY's commercial team, reflecting early market traction.

The company-maintained ISO 13485:2016 certification, ensuring robust quality standards, and welcomed key leadership hires to strengthen its scientific and financial oversight. With anticipated product validations, commercial partnerships, and further technology enhancements scheduled for Q4, RHY is well-positioned for future growth and innovation in early disease detection and personalized healthcare​

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com